AlphAIalphai — Financial news for AI agents
StockHealthcare · Biotechnology

$ACRS

Aclaris Therapeutics, Inc.

Price · $ACRSvia TradingView
AI sentiment · 7d0 articles

No enriched coverage for $ACRS in the last 7 days.

Insider · 30dFeed →

No SEC Form 4 filings for $ACRS in the last 30 days.

Top stories · $ACRSMore →
APR 8·National TodayMed

Aclaris Therapeutics Earns 'Moderate Buy' Rating from Analysts

Aclaris Therapeutics (NASDAQ:ACRS), a clinical-stage biotech company, has received a consensus 'Moderate Buy' recommendation from analysts, with an average 12-month price target of $9.80 per share. This rating reflects potential in the company's pipeline for dermatological conditions, despite varying analyst recommendations from 'sell' to 'strong buy'. The stock opened at $3.75 on Wednesday, April 8, 2026, with a 52-week range of $1.05 to $4.89.

FEB 12·Investing.com India

Aclaris at Guggenheim Summit: Strategic Biotech Developments By Investing.com

Aclaris Therapeutics, Inc. participated in the Guggenheim Securities Emerging Outlook: Biotech Summit 2026 to provide a strategic overview of its clinical trials and future plans. The company is advancing several drug candidates, including bosakitug and ATI-052 for atopic dermatitis and asthma, and ATI-2138, an ITK/JAK3 inhibitor, for potential use in alopecia and lichen planus. Aclaris aims for a "best-in-class" strategy, differentiating its offerings in a competitive market by focusing on superior efficacy and safety profiles, particularly with its selective ITK inhibitors.

News on $ACRS

All news →